

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5600074/aziz-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

196  
papers

2,310  
citations

24  
h-index

44  
g-index

200  
ext. papers

3,015  
ext. citations

3.5  
avg, IF

4.9  
L-index

#	Paper	IF	Citations
196	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. <i>Blood</i> , <b>2013</b> , 121, 4655-62	2.2	296
195	Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2745-2753	2.2	154
194	Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 276-81 <sup>1</sup>	7.1	114
193	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. <i>Blood</i> , <b>2013</b> , 121, 4867-74	2.2	110
192	hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies. <i>Cancer Cell</i> , <b>2015</b> , 28, 486-499	24.3	88
191	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. <i>Leukemia</i> , <b>2019</b> , 33, 1747-1758	10.7	88
190	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. <i>Blood</i> , <b>2015</b> , 126, 907-907	2.2	73
189	Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1831-1839	2.2	67
188	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , <b>2018</b> , 2, 1765-1772	7.8	63
187	Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. <i>Nature Communications</i> , <b>2017</b> , 8, 15102	17.4	61
186	EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. <i>Blood</i> , <b>2012</b> , 119, 4524-6	2.2	49
185	Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 416-422	1.9	42
184	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , <b>2020</b> , 7, e601-e612	14.6	41
183	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients $\geq 60$ years with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 961-6	7.1	39
182	Origins of myelodysplastic syndromes after aplastic anemia. <i>Blood</i> , <b>2017</b> , 130, 1953-1957	2.2	32
181	Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. <i>Haematologica</i> , <b>2012</b> , 97, 1242-5	6.6	32
180	Machine learning in haematological malignancies. <i>Lancet Haematology</i> , <b>2020</b> , 7, e541-e550	14.6	31

179	The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. <i>Haematologica</i> , <b>2016</b> , 101, e224-7	6.6	30
178	Consequences of mutant TET2 on clonality and subclonal hierarchy. <i>Leukemia</i> , <b>2018</b> , 32, 1751-1761	10.7	30
177	Acute myeloid leukemia in the elderly: do we know who should be treated and how?. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 979-87	1.9	29
176	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). <i>American Journal of Hematology</i> , <b>2016</b> , 91, 227-32	7.1	29
175	Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. <i>Nature Communications</i> , <b>2019</b> , 10, 5386	17.4	29
174	Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 1337-44	1.9	27
173	Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. <i>Blood</i> , <b>2018</b> , 132, 2100-2103	2.2	26
172	Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. <i>Haematologica</i> , <b>2013</b> , 98, 1686-8	6.6	22
171	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 4	7	21
170	Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. <i>Leukemia Research</i> , <b>2016</b> , 41, 43-7	2.7	21
169	Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS. <i>Current Hematologic Malignancy Reports</i> , <b>2017</b> , 12, 461-467	4.4	21
168	Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. <i>Blood</i> , <b>2020</b> , 136, 2249-2262	2.2	21
167	A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4231-4237	12.9	19
166	Chronic myelomonocytic leukemia: Forefront of the field in 2015. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 95, 222-42	7	19
165	The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 3437-9	1.9	19
164	The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , <b>2013</b> , 3, 218	5.3	19
163	Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). <i>Blood</i> , <b>2019</b> , 134, 678-678	2.2	19
162	Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?. <i>Oncologist</i> , <b>2015</b> , 20, 1069-76	5.7	18

161	Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1245-1253	7.1	18
160	Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. <i>Haematologica</i> , <b>2015</b> , 100, e434-7	6.6	18
159	A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes. <i>Blood</i> , <b>2018</b> , 132, 793-793	2.2	18
158	Invariant phenotype and molecular association of biallelic mutant myeloid neoplasia. <i>Blood Advances</i> , <b>2019</b> , 3, 339-349	7.8	18
157	Machine Learning in Oncology: What Should Clinicians Know?. <i>JCO Clinical Cancer Informatics</i> , <b>2020</b> , 4, 799-810	5.2	17
156	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1281-1286	4.4	17
155	Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 2537-9	1.9	16
154	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. <i>Blood Advances</i> , <b>2019</b> , 3, 4228-4237	7.8	16
153	Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. <i>Leukemia</i> , <b>2020</b> , 34, 957-962	10.7	16
152	Personalized predictions of patient outcomes during and after hospitalization using artificial intelligence. <i>Npj Digital Medicine</i> , <b>2020</b> , 3, 51	15.7	14
151	Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3737-3746	2.2	14
150	Molecular features of early onset adult myelodysplastic syndrome. <i>Haematologica</i> , <b>2017</b> , 102, 1028-1034	6.6	13
149	Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. <i>Communications Biology</i> , <b>2020</b> , 3, 493	6.7	13
148	Distinct clinical and biological implications of in myeloid neoplasms. <i>Blood Advances</i> , <b>2019</b> , 3, 2164-2178	7.8	12
147	The MDS genomics-prognosis symbiosis. <i>Hematology American Society of Hematology Education Program</i> , <b>2018</b> , 2018, 270-276	3.1	12
146	Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	11
145	Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications. <i>Oncologist</i> , <b>2015</b> , 20, 1154-60	5.7	11
144	Artificial Intelligence in Hematology: Current Challenges and Opportunities. <i>Current Hematologic Malignancy Reports</i> , <b>2020</b> , 15, 203-210	4.4	10

143	Impact of social media for the hematologist/oncologist. <i>Seminars in Hematology</i> , <b>2017</b> , 54, 193-197	4	10
142	Genomics of therapy-related myeloid neoplasms. <i>Haematologica</i> , <b>2020</b> , 105, e98-e101	6.6	10
141	Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 105, 112-7	7	9
140	Novel Machine Learning Can Predict Acute Asthma Exacerbation. <i>Chest</i> , <b>2021</b> , 159, 1747-1757	5.3	9
139	and mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 1587-1590	1.9	9
138	A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence. <i>Blood</i> , <b>2019</b> , 134, 2091-2091	2.2	8
137	Molecular landscape in acute myeloid leukemia: where do we stand in 2016. <i>Cancer Biology and Medicine</i> , <b>2016</b> , 13, 474-482	5.2	8
136	Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 1977-86	4	7
135	The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia. <i>Haematologica</i> , <b>2013</b> , 98, e131	6.6	7
134	TP53 Mutations and Outcome in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , <b>2016</b> , 128, 4336-4336	4.3	7
133	Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 2532-2539	1.9	6
132	Acute myeloid leukemia and artificial intelligence, algorithms and new scores. <i>Best Practice and Research in Clinical Haematology</i> , <b>2020</b> , 33, 101192	4.2	6
131	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 2139-2146	4.7	6
130	Impact of germline CTC1 alterations on telomere length in acquired bone marrow failure. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 935-939	4.5	5
129	Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons from Sequential Mutations. <i>Annual Review of Medicine</i> , <b>2017</b> , 68, 127-137	17.4	5
128	Paroxysmal nocturnal hemoglobinuria is not a cause of anemia in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 2215-6	1.9	5
127	Incorporation of Molecular Data into the Current Prognostic Models in Treated Patients with Myelodysplastic Syndromes: Which Model Is the Best. <i>Blood</i> , <b>2016</b> , 128, 50-50	2.2	5
126	Revised 15-item MDS-specific frailty scale maintains prognostic potential. <i>Leukemia</i> , <b>2020</b> , 34, 3434-3438	10.7	5

125	A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. <i>Blood</i> , <b>2016</b> , 128, 4320-4320	2.2	4
124	The Evolving Landscape of Myelodysplastic Syndrome Prognostication. <i>Clinical Hematology International</i> , <b>2020</b> , 2, 43-48	1.8	4
123	Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 318-322	4.5	3
122	Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?. <i>Oncologist</i> , <b>2016</b> , 21, 475-80	5.7	3
121	Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , <b>2018</b> , 13, 341-347	4.4	3
120	What Is the Optimal Time to Initiate Hypomethylating Agents (HMA) in Higher Risk Myelodysplastic Syndromes (MDS)?. <i>Blood</i> , <b>2018</b> , 132, 3098-3098	2.2	3
119	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee. <i>Blood</i> , <b>2018</b> , 132, 206-206	2.2	3
118	Fatigue in Chronic Myelogenous Leukemia Patients (pts) Treated with Tyrosine Kinase Inhibitors (TKI),. <i>Blood</i> , <b>2011</b> , 118, 3785-3785	2.2	3
117	Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA). <i>Blood</i> , <b>2014</b> , 124, 3273-3273	2.2	3
116	Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial. <i>Blood</i> , <b>2014</b> , 124, 978-978	2.2	3
115	The Revised International Prognostic Scoring System "Molecular" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , <b>2015</b> , 126, 607-607	2.2	3
114	PHF6 Somatic Mutations and Their Functional Role in the Pathophysiology of Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2016</b> , 128, 2736-2736	2.2	3
113	Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018?. <i>Acta Medica Academica</i> , <b>2019</b> , 48, 35-44	0.8	3
112	Novel Prognostic Models for Myelodysplastic Syndromes. <i>Hematology/Oncology Clinics of North America</i> , <b>2020</b> , 34, 369-378	3.1	3
111	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. <i>Blood</i> , <b>2021</b> , 138, 1885-1895	2.2	3
110	Chronic myelomonocytic leukemia: Are we finally solving the identity crisis?. <i>Blood Reviews</i> , <b>2016</b> , 30, 381-381	1.1	3
109	Improving Prognostic Modeling in Myelodysplastic Syndromes. <i>Current Hematologic Malignancy Reports</i> , <b>2016</b> , 11, 395-401	4.4	3
108	Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes. <i>Blood</i> , <b>2018</b> , 132, 1797-1797	2.2	2

107	Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , <b>2019</b> , 134, 4581-4581	2.2	2
106	Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms. <i>Blood</i> , <b>2019</b> , 134, 4238-4238	2.2	2
105	FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults. <i>Blood</i> , <b>2019</b> , 134, 452-452	2.2	2
104	The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy. <i>Blood</i> , <b>2019</b> , 134, 16-16	2.2	2
103	Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). <i>Blood</i> , <b>2019</b> , 134, 2716-2716	2.2	2
102	Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia. <i>Blood</i> , <b>2019</b> , 134, 2720-2720	2.2	2
101	Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma.. <i>Blood</i> , <b>2009</b> , 114, 2146-2146	2.2	2
100	A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). <i>Blood</i> , <b>2012</b> , 120, 3587-3587	2.2	2
99	Early Molecular and Cytogenetic Responses Predicts for Significantly Longer Event Free Survival (EFS) and Overall Survival (OS) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) In Analysis of 4 Tyrosine Kinase Inhibitor (TKI) Modalities (standard dose imatinib, high dose imatinib, dasatinib and nilotinib). <i>Blood</i> , <b>2012</b> , 120, 70-70	2.2	2
98	Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy. <i>Blood</i> , <b>2015</b> , 126, 1319-1319	2.2	2
97	Forty-Year Analysis of Randomized Clinical Trials in Patients with Acute Myeloid Leukemia Treated with Remission Induction Chemotherapy. <i>Blood</i> , <b>2016</b> , 128, 2786-2786	2.2	2
96	Clonal Dynamics of Refractory Aplastic Anemia in Patients Treated with Eltrombopag. <i>Blood</i> , <b>2016</b> , 128, 3892-3892	2.2	2
95	Extent and Clinical Implications of Subclonal Diversity in Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , <b>2017</b> , 130, 779-779	2.2	2
94	Does mutational burden add to other prognostic factors in MDS?. <i>Best Practice and Research in Clinical Haematology</i> , <b>2019</b> , 32, 101098	4.2	2
93	Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 735-738	1.9	2
92	Personalized Prediction of Hospital Mortality in COVID-19-Positive Patients. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , <b>2021</b> , 5, 795-801	3.1	2
91	A geno-clinical decision model for the diagnosis of myelodysplastic syndromes. <i>Blood Advances</i> , <b>2021</b> , 5, 4361-4369	7.8	2
90	Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1943-1953	1.9	1

89	A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia. <i>Blood</i> , <b>2020</b> , 136, 13-14	2.2	1
88	Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay. <i>Blood</i> , <b>2018</b> , 132, 4806-4806	2.2	1
87	Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2 mutations after Intensive Chemotherapy. <i>Blood</i> , <b>2018</b> , 132, 1389-1389	2.2	1
86	Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential. <i>Blood</i> , <b>2018</b> , 132, 3084-3084	2.2	1
85	RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. <i>Blood</i> , <b>2019</b> , 134, 2696-2696	2.2	1
84	Epigenomic Signatures in Myelodysplastic Syndrome Patients As Predictors of Donor Compatibility and Transplant Outcome. <i>Blood</i> , <b>2019</b> , 134, 4557-4557	2.2	1
83	How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS. <i>Blood</i> , <b>2019</b> , 134, 1716-1716	2.2	1
82	Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia. <i>Blood</i> , <b>2019</b> , 134, 1405-1405	2.2	1
81	A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure. <i>Blood</i> , <b>2020</b> , 136, 1-1	2.2	1
80	Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.. <i>Blood</i> , <b>2012</b> , 120, 2616-2616	2.2	1
79	Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients With higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy. <i>Blood</i> , <b>2013</b> , 122, 1525-1525	2.2	1
78	hnRNP K: A Novel Regulator of Hematopoiesis and A Potential Predictive Biomarker In Acute Myeloid Leukemia. <i>Blood</i> , <b>2013</b> , 122, 226-226	2.2	1
77	Early Results Of a Phase I/II Trial Of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) For Patients (Pts) With Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , <b>2013</b> , 122, 3949-3949	2.2	1
76	An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies. <i>Blood</i> , <b>2014</b> , 124, 530-530	2.2	1
75	PHF6 - Somatic Mutations and Their Role in Pathophysiology of MDS and AML. <i>Blood</i> , <b>2015</b> , 126, 1259-1259	2.2	1
74	TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition. <i>Blood</i> , <b>2015</b> , 126, 1645-1645	2.2	1
73	Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia. <i>Blood</i> , <b>2015</b> , 126, 300-300	2.2	1
72	Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage. <i>Blood</i> , <b>2016</b> , 128, 1659-1659	2.2	1



71	U2AF1 Mutations in S34 and Q157 Create Distinct Molecular and Clinical Contexts. <i>Blood</i> , <b>2016</b> , 128, 3155-3155	2.2	1
70	Pathogenic Relevance of Germ Line TET2 Alterations. <i>Blood</i> , <b>2016</b> , 128, 3160-3160	2.2	1
69	Analysis of Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated in Randomized Clinical Trials. <i>Blood</i> , <b>2016</b> , 128, 4000-4000	2.2	1
68	Clonal Events of Aplastic Anemia Related to the Evolution to Myelodysplastic Syndrome. <i>Blood</i> , <b>2016</b> , 128, 4290-4290	2.2	1
67	SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial. <i>Blood</i> , <b>2019</b> , 134, 2651-2651	2.2	1
66	APC mutations in myeloid malignancies: Incidence and impact on leukemogenesis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 11047-11047	2.2	1
65	Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , <b>2016</b> , 128, 4332-4332	2.2	1
64	Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy. <i>Blood</i> , <b>2013</b> , 122, 2788-2788	2.2	1
63	What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 2762-2767	1.9	1
62	What is machine learning?. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , <b>2021</b> ,	0.5	1
61	Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 659.e1-659.e6		1
60	Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?. <i>Blood</i> , <b>2019</b> , 134, 1270e.1270	2.2	0
59	Simplified Pediatric Index of Mortality 3 Score by Explainable Machine Learning Algorithm <b>2021</b> , 3, e0561		0
58	Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases. <i>Blood</i> , <b>2018</b> , 132, 4345-4345	2.2	0
57	Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?. <i>Blood</i> , <b>2019</b> , 134, 381-381	2.2	0
56	First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia. <i>Blood</i> , <b>2019</b> , 134, 3920-3920	2.2	0
55	Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors. <i>Blood</i> , <b>2019</b> , 134, 2985-2985	2.2	0
54	Prognostic Implication of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype (MK) in Patients with Acute Myeloid Leukemia (AML) and Complex Cytogenetics. <i>Blood</i> , <b>2011</b> , 118, 1495-1495	2.2	0

53	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 917.e1-917.e9	0
52	The Genomic Landscape of WilmsTumor 1 (WT1) Mutant Acute Myeloid Leukemia. <i>Blood</i> , <b>2020</b> , 136, 28-28	2.2
51	TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity. <i>Blood</i> , <b>2020</b> , 136, 2-3	2.2
50	Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS). <i>Blood</i> , <b>2018</b> , 132, 104-104	2.2
49	TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer. <i>Blood</i> , <b>2018</b> , 132, 2270-2270	2.2
48	Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype. <i>Blood</i> , <b>2018</b> , 132, 2809-2809	2.2
47	Distinct Features of Chip-Derived and De Novo MDS. <i>Blood</i> , <b>2018</b> , 132, 2572-2572	2.2
46	BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden. <i>Blood</i> , <b>2018</b> , 132, 4352-4352	2.2
45	Does Trial Participation Improve Outcomes for Higher-Risk Myelodysplastic Syndromes (MDS) Patients Treated at Specialty Centers?. <i>Blood</i> , <b>2018</b> , 132, 3096-3096	2.2
44	Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes. <i>Blood</i> , <b>2018</b> , 132, 1805-1805	2.2
43	Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML. <i>Blood</i> , <b>2018</b> , 132, 4353-4353	2.2
42	Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?. <i>Blood</i> , <b>2018</b> , 132, 900-900	2.2
41	Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation. <i>Blood</i> , <b>2018</b> , 132, 4346-4346	2.2
40	Molecular Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutations. <i>Blood</i> , <b>2018</b> , 132, 4389-4389	2.2
39	Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA. <i>Blood</i> , <b>2018</b> , 132, 3095-3095	2.2
38	Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. <i>Blood</i> , <b>2018</b> , 132, 2075-2075	2.2
37	Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS. <i>Blood</i> , <b>2018</b> , 132, 3074-3074	2.2
36	Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States. <i>Blood</i> , <b>2018</b> , 132, 2298-2298	2.2

35	Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. <i>Blood</i> , <b>2018</b> , 132, 1527-1527	2.2
34	Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia. <i>Blood</i> , <b>2018</b> , 132, 3869-3869	2.2
33	Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis. <i>Blood</i> , <b>2018</b> , 132, 4805-4805	2.2
32	Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis. <i>Blood</i> , <b>2019</b> , 134, 1406-1406	2.2
31	Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications. <i>Blood</i> , <b>2019</b> , 134, 4221-4221	2.2
30	The Biological Inferences from the Ranking of SF3B1 Mutations in the Clonal Hierarchy of Myeloid Neoplasia. <i>Blood</i> , <b>2019</b> , 134, 5411-5411	2.2
29	Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features. <i>Blood</i> , <b>2019</b> , 134, 2992-2992	2.2
28	Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies. <i>Blood</i> , <b>2019</b> , 134, 3433-3433	2.2
27	ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia. <i>Blood</i> , <b>2019</b> , 134, 4233-4233	2.2
26	Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential. <i>Blood</i> , <b>2019</b> , 134, 3743-3743	2.2
25	Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI). <i>Blood</i> , <b>2019</b> , 134, 2089-2089	2.2
24	Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2019</b> , 134, 4599-4599	2.2
23	A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. <i>Blood</i> , <b>2019</b> , 134, 2595-2595	2.2
22	Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients. <i>Blood</i> , <b>2019</b> , 134, 3836-3836	2.2
21	Molecular dissection of normal karyotype acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 7534-7534	2.2
20	A personalized prediction model for hospital readmission risk for cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 7057-7057	2.2
19	Different Genomic Patterns in Patients with Primary Acute Myeloid Leukemia (AML) Compared to Secondary AML in Patients with Normal Karyotype. <i>Blood</i> , <b>2014</b> , 124, 1054-1054	2.2
18	Impact of STAT3 Mutations on Clinical Features and Treatment Outcomes in Large Granular Lymphocyte Leukemia. <i>Blood</i> , <b>2015</b> , 126, 2216-2216	2.2

17	hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML. <i>Blood</i> , <b>2015</b> , 126, 439-439	2.2
16	Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes. <i>Blood</i> , <b>2015</b> , 126, 611-611	2.2
15	A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2016</b> , 128, 4065-4065	2.2
14	Distinct Clinical and Biological Implications of Various DNTMT3A Mutations in Myeloid Neoplasms. <i>Blood</i> , <b>2016</b> , 128, 2872-2872	2.2
13	BCOR and BCORL1 mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes. <i>Blood</i> , <b>2016</b> , 128, 4293-4293	2.2
12	Using Machine Intelligence Algorithms to Develop a Geno-Clinical Model to Predict Responses to Hypomethylating Agents in Myelodysplastic Syndromes. <i>Blood</i> , <b>2016</b> , 128, 3193-3193	2.2
11	Landscape of Subclonal Mutations in Myelodysplastic Syndromes (MDS) Allows for a Novel Hierarchy of Clonal Advantage By Combining Germline and Somatic Mutations. <i>Blood</i> , <b>2016</b> , 128, 957-957 <sup>2,2</sup>	2.2
10	The Optimal Timing for Stem Cell Collection After Induction Therapy for Patients with Multiple Myeloma. <i>Blood</i> , <b>2010</b> , 116, 2252-2252	2.2
9	Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2011</b> , 118, 1550-1550	2.2
8	Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs). <i>Blood</i> , <b>2012</b> , 120, 3757-3757	2.2
7	Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21. <i>Blood</i> , <b>2012</b> , 120, 1488-1488	2.2
6	Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients . <i>Blood</i> , <b>2012</b> , 120, 43-43	2.2
5	Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Blood</i> , <b>2012</b> , 120, 3554-3554	2.2
4	Clofarabine Plus Low-Dose Cytarabine Induction Followed By Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine Consolidation In Acute Myeloid Leukemia Frontline Therapy For Older Patients. <i>Blood</i> , <b>2013</b> , 122, 3948-3948	2.2
3	Should I rock the boat? When to stop TKIs in CML. <i>Blood</i> , <b>2021</b> , 137, 1136-1137	2.2
2	Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 229-233	1.9
1	Online and Social Media Resources for Patients with MDS. <i>Current Hematologic Malignancy Reports</i> , <b>2018</b> , 13, 570-575	4.4